Low-Dose Levothyroxine Reduces Intrahepatic Lipid Content in Patients With Type 2 Diabetes Mellitus and NAFLD
Open accessThe DOI matches its Crossref record; 38 of the 39 references it cites were found in a registry or an index.
Abstract
Context: Nonalcoholic fatty liver disease (NAFLD) is highly prevalent in patients with type 2 diabetes mellitus (T2DM) and associated with significant morbidity and mortality. Thyroid hormone (TH) increases β-oxidation of fatty acids and decreases intrahepatic lipid content (IHLC) in rodents with NAFLD. Objective: We investigated the possibility of low intrahepatic TH concentration in NAFLD and studied the effect of TH treatment in humans. Design/Setting: This was a phase 2b single-arm study in six hospitals in Singapore. Intrahepatic thyroid hormone concentrations were measured in rats with induced NAFLD. Patients: Euthyroid patients with T2DM and steatosis measured by ultrasonography. Intervention: Levothyroxine was titrated to reach a thyroid-stimulating hormone level of 0.34 to 1.70 mIU/L before a 16-week maintenance phase. Main Outcome Measures: The primary outcome measure was change in IHLC measured by proton magnetic resonance spectroscopy after treatment. Results: Twenty male patients were included in the per-protocol analysis [mean ± SD: age, 47.8 ± 7.8 years; body mass index (BMI), 30.9 ± 4.4 kg/m2; baseline IHLC, 13% ± 4%]. After treatment, IHLC was decreased 12% (±SEM, 26%) relative to baseline (absolute change, -2%; 95% CI, -3 to 0; P = 0.046). Small decreases in BMI (P = 0.044), visceral adipose tissue volume (P = 0.047), and subcutaneous adipose tissue volume (P = 0.045) were observed. No significant changes in glucose regulation or lipid profile occurred. Conclusion: This study demonstrated the efficacy and safety of low-dose TH therapy for NAFLD in men. TH or TH analogs may be beneficial for this condition.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In humans, hypothyroidism is associated with a poor prognosis in established heart failure (33) and TH can reduce intrahepatic triglyceride content (34,35).”
From Evidence-Based Use of Levothyroxine/Liothyronine Combinations in Treating Hypothyroidism: A Consensus Document (2021) · cites this paper as [35]
In the citing paper
“Indeed, low-dose LT4 reduces intrahepatic lipid content in patients with type 2 diabetes mellitus and metabolic (dysfunction)-associated fatty liver disease (77), whereas the opposite is observed in patients with resistance to TH (78).”
From Emerging Therapies in Hypothyroidism (2024) · cites this paper as [77]
In the citing paper
“LT4 also reduced intrahepatic lipid content in an uncontrolled study in euthyroid subjects with non-alcoholic fatty liver disease and type 2 diabetes”
From Pharmacodynamic and Therapeutic Actions of Levothyroxine (2021) · cites this paper as [45]
In the citing paper
“and TH can reduce intrahepatic triglyceride content [34, 35].”
From Evidence-Based Use of Levothyroxine/Liothyronine Combinations in Treating Hypothyroidism: A Consensus Document (2021) · cites this paper as [35]
Citations
Cites
Younossi, Z. M., Koenig, A. B., Abdelatif, D., Fazel, Y., Henry, L., & Wymer, M. (2016) · Hepatology · doi:10.1002/hep.28431 · Cited by 10,781
Chalasani, N., Younossi, Z., Lavine, J. E., Charlton, M., Cusi, K., Rinella, M., Harrison, S. A., Brunt, E. M., & Sanyal, A. J. (2018) · Hepatology · doi:10.1002/hep.29367 · Cited by 7,239
Szczepaniak, L. S., Nurenberg, P., Leonard, D., Browning, J. D., Reingold, J. S., Grundy, S., Hobbs, H. H., & Dobbins, R. L. (2005) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00064.2004 · Cited by 1,562
The pathogenesis of insulin resistance: integrating signaling pathways and substrate flux
Samuel, V. T., & Shulman, G. I. (2016) · Journal of Clinical Investigation · doi:10.1172/jci77812 · Cited by 1,484
Lim, E. L., Hollingsworth, K. G., Aribisala, B. S., Chen, M. J., Mathers, J. C., & Taylor, R. (2011) · Diabetologia · doi:10.1007/s00125-011-2204-7 · Cited by 1,164
Petersen, K. F., Dufour, S., Befroy, D., Lehrke, M., Hendler, R. E., & Shulman, G. I. (2005) · Diabetes · doi:10.2337/diabetes.54.3.603 · Cited by 911
Direct effects of thyroid hormones on hepatic lipid metabolism
Sinha, R. A., Singh, B. K., & Yen, P. M. (2018) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2018.10 · Cited by 660
Self-citationTargher, G., Bertolini, L., Poli, F., Rodella, S., Scala, L., Tessari, R., Zenari, L., & Falezza, G. (2005) · Diabetes · doi:10.2337/diabetes.54.12.3541 · Cited by 574
Portillo-Sanchez, P., Bril, F., Maximos, M., Lomonaco, R., Biernacki, D., Orsak, B., Subbarayan, S., Webb, A., Hecht, J., & Cusi, K. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-1966 · Cited by 503
Studies of insulin resistance in patients with clinical and subclinical hypothyroidism
Maratou, E., Hadjidakis, D. J., Kollias, A., Tsegka, K., Peppa, M., Alevizaki, M., Mitrou, P., Lambadiari, V, Boutati, E., Nikzas, D., et al. (2009) · European Journal of Endocrinology · doi:10.1530/eje-08-0797 · Cited by 455
Cited by
Sinha, R. A., Bruinstroop, E., Singh, B. K., & Yen, P. M. (2019) · Thyroid · doi:10.1089/thy.2018.0664 · Cited by 271
Self-citationHutchison, A. L., Tavaglione, F., Romeo, S., & Charlton, M. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.08.030 · Cited by 250
Novel therapeutic targets for cholestatic and fatty liver disease
Trauner, M., & Fuchs, C. D. (2022) · Gut · doi:10.1136/gutjnl-2021-324305 · Cited by 204
Thyroid hormone signaling and the liver
Ritter, M. J., Amano, I., Hollenberg, A. N., et al. (2020) · Hepatology · doi:10.1002/hep.31296 · Cited by 188
Jonklaas, J., Bianco, A. C., Cappola, A. R., Celi, F. S., Fliers, E., Heuer, H., McAninch, E. A., Moeller, L. C., Nygaard, B., Sawka, A. M., et al. (2021) · Thyroid® · doi:10.1089/thy.2020.0720 · Cited by 172
Metadata
- Authors
- Bruinstroop, E., Dalan, R., Cao, Y., Bee, Y. M., Chandran, K., Cho, L. W., Soh, S. B., Teo, E. K., Toh, S.-A., Leow, M. K. S., Sinha, R. A., Sadananthan, S. A., Michael, N., Stapleton, H. M., Leung, C., Angus, P. W., Patel, S. K., Burrell, L. M., Lim, S. C., Sum, C. F., Velan, S. S., & Yen, P. M.
- Affiliations
- Duke-NUS Medical School (SG)
- Nanyang Technological University (SG)
- Singapore Clinical Research Institute (SG)
- Singapore General Hospital (SG)
- Ng Teng Fong General Hospital (SG)
- Changi General Hospital (SG)
- National University Health System (SG)
- Agency for Science, Technology and Research (SG)
- Duke University (US)
- The University of Melbourne (AU)
- Khoo Teck Puat Hospital (SG)
- Corresponding author
- Yen, Paul M
- ORCID
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2018-04-27
- Volume
- 103
- Issue
- 7
- Pages
- 2698-2706
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2802921027
- Cited by
- 108
- References
- 39
- Citations by year
- 2026: 7 · 2025: 14 · 2024: 18 · 2023: 18 · 2022: 12 · 2021: 16 · 2020: 11 · 2019: 10 · 2018: 2
- FWCI
- 7.61
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (publishedVersion, cc-by)
- National University of Singapore (submittedVersion)
- Funders
- Duke-NUS Medical School
- Koninklijke Nederlandse Akademie van Wetenschappen
- Medical Research Council
- National Health and Medical Research Council (629025, 1029990)
- National Medical Research Council
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Disorders and Treatments
- Health Sciences › Medicine › Pathology and Forensic Medicine › Alcohol Consumption and Health Effects
- Keywords
- levothyroxine, non-alcoholic fatty liver disease, type 2 diabetes, thyroid hormone replacement, hepatic steatosis, thyroid-stimulating hormone, fatty acid beta-oxidation, visceral adipose tissue, subcutaneous adipose tissue, 1H NMR
- MeSH terms
- Adult, Diabetes Mellitus, Type 2, Humans, Lipids, Liver, Male, Middle Aged, Thyroxine, Treatment Outcome, Young Adult, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Low-Dose Levothyroxine Reduces Intrahepatic Lipid Content in Patients With Type 2 Diabetes Mellitus and NAFLD. https://app.cochat.ai/papers/10.1210/jc.2018-00475
- The paper
- Bruinstroop, E., Dalan, R., Cao, Y., Bee, Y. M., Chandran, K., Cho, L. W., Soh, S. B., Teo, E. K., Toh, S.-A., Leow, M. K. S., Sinha, R. A., Sadananthan, S. A., Michael, N., Stapleton, H. M., Leung, C., Angus, P. W., Patel, S. K., Burrell, L. M., Lim, S. C., . . . Yen, P. M. (2018). Low-Dose Levothyroxine Reduces Intrahepatic Lipid Content in Patients With Type 2 Diabetes Mellitus and NAFLD. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/jc.2018-00475
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.